

# Shenhong Wu

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4599872/shenhong-wu-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

93  
papers

5,093  
citations

33  
h-index

71  
g-index

94  
ext. papers

5,642  
ext. citations

5.5  
avg, IF

5.7  
L-index

#	Paper	IF	Citations
93	Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2008</b> , 300, 2277-85	27.4	568
92	Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. <i>American Journal of Kidney Diseases</i> , <b>2007</b> , 49, 186-93	7.4	472
91	Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. <i>Lancet Oncology, The</i> , <b>2009</b> , 10, 559-68	21.7	334
90	Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 487-94	27.4	329
89	Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. <i>Lancet Oncology, The</i> , <b>2008</b> , 9, 117-23	21.7	310
88	Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. <i>Oncologist</i> , <b>2008</b> , 13, 1001-11	5.7	273
87	Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. <i>Acta Oncologica</i> , <b>2009</b> , 48, 9-17	3.2	251
86	Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials. <i>Acta Oncologica</i> , <b>2010</b> , 49, 287-97	3.2	217
85	The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. <i>Immunity</i> , <b>2005</b> , 23, 29-40	32.3	182
84	Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. <i>American Journal of Hypertension</i> , <b>2010</b> , 23, 460-8	2.3	179
83	Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis. <i>Acta Oncologica</i> , <b>2008</b> , 47, 176-86	3.2	169
82	Bevacizumab increases risk for severe proteinuria in cancer patients. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2010</b> , 21, 1381-9	12.7	163
81	Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 3144-55	2.2	105
80	The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , <b>2013</b> , 69, e121-8	4.5	100
79	Use of receptor antibodies to demonstrate membrane glucocorticoid receptor in cells from human leukemic patients. <i>FASEB Journal</i> , <b>1993</b> , 7, 1283-92	0.9	100
78	Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. <i>Cancer Treatment Reviews</i> , <b>2011</b> , 37, 312-20	14.4	78
77	Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 1078-86	4.3	76

76	Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. <i>Clinical Genitourinary Cancer</i> , <b>2009</b> , 7, 11-9	3.3	72
75	Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , <b>2013</b> , 69, 708-720	4.5	71
74	Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy. <i>Cancer</i> , <b>2009</b> , 115, 1286-99	6.4	65
73	Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. <i>Oncologist</i> , <b>2011</b> , 16, 543-53	5.7	65
72	New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy. <i>Journal of Hematology and Oncology</i> , <b>2017</b> , 10, 38	22.4	50
71	The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , <b>2012</b> , 67, 400-8	4.5	50
70	The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. <i>Investigational New Drugs</i> , <b>2013</b> , 31, 787-97	4.3	49
69	The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. <i>Investigational New Drugs</i> , <b>2012</b> , 30, 1773-81	4.3	44
68	The use of bisphosphonates in cancer patients. <i>Acta Oncologica</i> , <b>2007</b> , 46, 581-91	3.2	42
67	Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 1125-33	5.6	41
66	Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. <i>BJU International</i> , <b>2007</b> , 99, 1047-55	5.6	41
65	Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , <b>2017</b> , 77, 902-910.e2	4.5	39
64	The efficacy of temozolomide for recurrent glioblastoma multiforme. <i>European Journal of Neurology</i> , <b>2013</b> , 20, 223-30	6	37
63	Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4. <i>Dermatologic Therapy</i> , <b>2013</b> , 26, 135-48	2.2	37
62	Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients. <i>Acta Oncologica</i> , <b>2013</b> , 52, 1202-12	3.2	36
61	Alopecia with endocrine therapies in patients with cancer. <i>Oncologist</i> , <b>2013</b> , 18, 1126-34	5.7	35
60	Individual hydrogen bonds play a critical role in MHC class II: peptide interactions: implications for the dynamic aspects of class II trafficking and DM-mediated peptide exchange. <i>Immunological Reviews</i> , <b>1999</b> , 172, 239-53	11.3	33
59	Incidence and risk of xerosis with targeted anticancer therapies. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 656-67	4.5	30

58	Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization. <i>European Journal of Haematology</i> , <b>2013</b> , 90, 142-50	3.8	26
57	Alteration of a single hydrogen bond between class II molecules and peptide results in rapid degradation of class II molecules after invariant chain removal. <i>Journal of Experimental Medicine</i> , <b>1998</b> , 188, 2139-49	16.6	25
56	Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , <b>2012</b> , 135, 347-54	4.4	24
55	Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. <i>Cancer Investigation</i> , <b>2015</b> , 33, 70-7	2.1	23
54	Emerging therapeutic agents for genitourinary cancers. <i>Journal of Hematology and Oncology</i> , <b>2019</b> , 12, 89	22.4	22
53	Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma. <i>Biomarker Research</i> , <b>2015</b> , 3, 5	8	21
52	Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , <b>2014</b> , 37, 266-71	2.7	18
51	Inverse association between eczema and meningioma: a meta-analysis. <i>Cancer Causes and Control</i> , <b>2011</b> , 22, 1355-63	2.8	18
50	Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer. <i>Cancer Investigation</i> , <b>2016</b> , 34, 521-530	2.1	15
49	Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases. <i>Clinical Genitourinary Cancer</i> , <b>2007</b> , 5, 403-5	3.3	14
48	Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma. <i>Current Oncology Reports</i> , <b>2018</b> , 20, 41	6.3	13
47	Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis. <i>Acta Oncologica</i> , <b>2011</b> , 50, 997-1005	3.2	12
46	Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis. <i>Acta Oncologica</i> , <b>2016</b> , 55, 1196-1203	3.2	12
45	Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis. <i>Clinical Hypertension</i> , <b>2019</b> , 25, 12	4.8	10
44	Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials. <i>Acta Oncologica</i> , <b>2015</b> , 54, 124-32	3.2	9
43	The MHC class II-associated invariant chain-derived peptide clip binds to the peptide-binding groove of class II molecules. <i>Molecular Immunology</i> , <b>1996</b> , 33, 371-7	4.3	9
42	Risk of Liver Toxicity with Nivolumab Immunotherapy in Cancer Patients. <i>Oncology</i> , <b>2018</b> , 94, 259-273	3.6	8
41	Replacement of the membrane proximal region of I-A(d) MHC class II molecule with I-E-derived sequences promotes production of an active and stable soluble heterodimer without altering peptide-binding specificity. <i>Journal of Immunological Methods</i> , <b>2005</b> , 300, 74-92	2.5	8

40	Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events. <i>Cancer Investigation</i> , <b>2011</b> , 29, 460-71	2.1	8
39	Fatal Adverse Events Associated with Pembrolizumab in Cancer Patients: A Meta-Analysis. <i>Cancer Investigation</i> , <b>2020</b> , 38, 130-138	2.1	7
38	Increased Risk of Hypertension with Enzalutamide in Prostate Cancer: A Meta-Analysis. <i>Cancer Investigation</i> , <b>2019</b> , 37, 478-488	2.1	5
37	Novel therapy for advanced gastric cancer. <i>World Journal of Gastrointestinal Oncology</i> , <b>2015</b> , 7, 263-70	3.4	5
36	Comparative analysis of the effectiveness of abiraterone before and after docetaxel in patients with metastatic castration-resistant prostate cancer. <i>World Journal of Clinical Oncology</i> , <b>2015</b> , 6, 64-72	2.5	5
35	Risk of anemia attributable to everolimus in patients with cancer: a meta-analysis of randomized controlled trials. <i>Anticancer Research</i> , <b>2015</b> , 35, 2333-40	2.3	5
34	Risk of hypertension in Cancer patients treated with Abiraterone: a meta-analysis. <i>Clinical Hypertension</i> , <b>2019</b> , 25, 5	4.8	4
33	Rash to mTOR inhibitor everolimus: Systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e19624-e19624	2.2	4
32	Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis. <i>Cancer Investigation</i> , <b>2017</b> , 35, 552-561	2.1	3
31	Bevacizumab and Cancer Treatment-Related MortalityReply. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 305, 2291	27.4	3
30	Cutaneous metastasis as an initial presentation of lung adenocarcinoma with KRAS mutation: a case report and literature review. <i>Stem Cell Investigation</i> , <b>2014</b> , 1, 6	5.1	3
29	Incidence and risk of developing photosensitivity with targeted anticancer therapies. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 81, 1009-1011	4.5	2
28	Bevacizumab and risk of hand-foot syndrome associated with chemotherapy.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e13591-e13591	2.2	2
27	Risk of serious infection with mTOR inhibitors everolimus and temsirolimus in the treatment of cancer: A meta-analysis of randomized controlled trials.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 2604-2604 <sup>2</sup>	2.2	2
26	An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 695-705	5.4	2
25	Risk of Venous Thromboembolism with Thalidomide in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Blood</i> , <b>2008</b> , 112, 3820-3820	2.2	1
24	Increased risk of liver toxicity secondary to nivolumab therapy in the treatment of cancer.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e14559-e14559	2.2	1
23	Fatal adverse events associated with pembrolizumab in cancer patients: A meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2561-2561	2.2	1

22	Discontinuation of everolimus due to unrelated adverse events in cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e14020-e14020	2.2	○
21	Improving tolerability of pembrolizumab with weight based dosing: A meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2639-2639	2.2	○
20	Tolerability of axitinib in advanced renal cell carcinoma: A meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e16536-e16536	2.2	○
19	Ibrutinib-associated dermatologic toxicities: A systematic review and meta-analysis.. <i>Critical Reviews in Oncology/Hematology</i> , <b>2022</b> , 174, 103696	7	○
18	Risks and management of hypertension in cancer patients undergoing targeted therapy: a review.. <i>Clinical Hypertension</i> , <b>2022</b> , 28, 14	4.8	○
17	Reply to: "Skin moisturization for xerosis related to targeted anticancer therapies". <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 73, e35-6	4.5	
16	Tolerability of single agent nivolumab in cancer patients: A meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e15146-e15146	2.2	
15	Tolerability of enzalutamide in prostate cancer: A meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e15629-e15629	2.2	
14	Risk of hypocalcemia in cancer patients treated with cabozantinib: A meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e17067-e17067	2.2	
13	Tolerability of dual checkpoint blockade with nivolumab and ipilimumab: A meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e15149-e15149	2.2	
12	Risk of serious anemia with mTOR inhibitors in cancer patients: A meta-analysis of randomized controlled trials.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e13534-e13534	2.2	
11	Incidence and risk of stomatitis to mTOR inhibitors in cancer patients: A meta-analysis of randomized controlled trials.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e17572-e17572	2.2	
10	Risk of severe diarrhea associated with ipilimumab in cancer patients.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 9634-9634	2.2	
9	Incidence and risk of rash to mTOR inhibitors in cancer patients: A meta-analysis of randomized controlled trials.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, e17585-e17585	2.2	
8	Comparative effectiveness of enzalutamide before and after chemotherapy in patients with metastatic castration-resistant prostate cancer: A meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e16001-e16001	2.2	
7	Risk of pneumonitis attributable to everolimus in cancer patients: A meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e13574-e13574	2.2	
6	Risk of hyperglycemia attributable to everolimus in renal cell and nonrenal cell carcinoma patients: A meta-analysis.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 515-515	2.2	
5	Risk of Skin Rash in Proteasome Inhibitor Bortezomib: A Systematic Literature Review and Meta-Analysis. <i>Blood</i> , <b>2011</b> , 118, 5120-5120	2.2	

- 4 Risk of rash with nilotinib: A systematic review of the literature and meta-analysis.. *Journal of Clinical Oncology*, **2012**, 30, 9088-9088 2.2
- 3 Risk of mineralocorticoid excess syndrome with CYP17 inhibitor abiraterone in prostate cancer patients.. *Journal of Clinical Oncology*, **2012**, 30, e15140-e15140 2.2
- 2 Risk of rash associated with lenalidomide in multiple myeloma and myelodysplastic syndrome: A systematic review of the literature and meta-analysis.. *Journal of Clinical Oncology*, **2012**, 30, e18571-e18571 2.2
- 1 Risk of skin rash with the proteasome inhibitor bortezomib: Updated systematic review and meta-analysis.. *Journal of Clinical Oncology*, **2012**, 30, 9092-9092 2.2